Core Viewpoint - The company plans to invest RMB 40 million as a limited partner in the Shanghai Haiwang Hezhong Private Equity Fund, which focuses on industries related to integrated circuits, high-end manufacturing, and biomedicine, aligning with the company's main business [1][3][19]. Investment Overview - The investment will constitute approximately 1.8957% of the total subscribed capital of the fund, which is set at RMB 2.11 billion [1][7]. - The investment aims to leverage the expertise and resources of professional investment institutions to optimize the company's investment structure and capture industry opportunities [3][17]. Related Party Transactions - The limited partner Shanghai Pudong Science and Technology Innovation Group, a shareholder of the company, holds 604,731 shares, representing 0.14% of the company [2][4]. - The transaction is classified as a related party transaction but does not constitute a major asset restructuring as per regulations [2][5][19]. Approval Process - The transaction has been approved by the company's board of directors and independent directors, with the related party abstaining from voting [2][19]. - The approval process complies with relevant regulations and does not require shareholder meeting approval [19][20]. Fund Management and Structure - The fund will have a management fee of 2% per year based on the subscribed capital during the investment period [11][12]. - The fund's investment period is set for five years, with a total duration of eight years unless extended [9][14]. Financial Impact - The investment will not be consolidated into the company's financial statements and will not impose financial pressure on the company's existing operations [17][19]. - The investment is expected to enhance the company's market competitiveness and investment strategies without adversely affecting shareholder interests [19][20].